These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 16759612)

  • 1. [Nuclear medicine and lymphoma].
    Fernández de Sevilla Ribosa A
    Rev Esp Med Nucl; 2006; 25(2):77-9. PubMed ID: 16759612
    [No Abstract]   [Full Text] [Related]  

  • 2. [Radioimmunotherapy for non-Hodgkin lymphoma: historical development and current status].
    Emmanouilides C
    Rev Esp Med Nucl; 2006; 25(1):42-54. PubMed ID: 16540013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Radioimmunotherapy for B-cell lymphoma].
    Tobinai K
    Rinsho Ketsueki; 2006 Jun; 47(6):463-70. PubMed ID: 16862974
    [No Abstract]   [Full Text] [Related]  

  • 4. [Radioimmunotherapy in non-Hodgkin's lymphoma. With focus on anti-CD20 treatment].
    de Nully Brown P; Jurlander J; Lindén O; Hansen M
    Ugeskr Laeger; 2005 Oct; 167(41):3867-9. PubMed ID: 16221425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical development of radioimmunotherapy for B-cell non-Hodgkin's lymphoma.
    Meredith RF; Knox SJ
    Int J Radiat Oncol Biol Phys; 2006; 66(2 Suppl):S15-22. PubMed ID: 16979433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dosimetry in patients with B-cell lymphoma treated with [(90)Y]ibritumomab tiuxetan or [(131)I]tositumomab.
    Sjögreen-Gleisner K; Dewaraja YK; Chiesa C; Tennvall J; Lindén O; Strand SE; Ljungberg M
    Q J Nucl Med Mol Imaging; 2011 Apr; 55(2):126-54. PubMed ID: 21386787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Radioimmunotherapy with (90)Y-ibritumomab tiuxetan (Zevalin). Spanish Nuclear Medicine Society].
    Bello P; Almoguera MI; Pajares M; Olivas C; Lapeña L; Freire JM;
    Rev Esp Med Nucl; 2010; 29(1):50-2. PubMed ID: 19963305
    [No Abstract]   [Full Text] [Related]  

  • 8. Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphoma.
    Gordon LI; Witzig TE; Wiseman GA; Flinn IW; Spies SS; Silverman DH; Emmanouilides C; Cripe L; Saleh M; Czuczman MS; Olejnik T; White CA; Grillo-López AJ
    Semin Oncol; 2002 Feb; 29(1 Suppl 2):87-92. PubMed ID: 11842394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Contribution of radioimmunotherapy to the treatment of lymphoma].
    Rizzo-Padoin N
    Ann Pharm Fr; 2008; 66(5-6):300-8. PubMed ID: 19061730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Targeted destruction of lymphomas with the aid of radioimmunotherapy. Tumor antibodies isotope taxi].
    MMW Fortschr Med; 2004 Apr; 146(15):66. PubMed ID: 15373026
    [No Abstract]   [Full Text] [Related]  

  • 11. [Radioimmunotherapy with (90)Y-Ibritumomab tiuxetan].
    Brockmann H; Biersack HJ
    Dtsch Med Wochenschr; 2006 Mar; 131(9):438-40. PubMed ID: 16493567
    [No Abstract]   [Full Text] [Related]  

  • 12. Radiobiology of radioimmunotherapy: targeting CD20 B-cell antigen in non-Hodgkin's lymphoma.
    Hernandez MC; Knox SJ
    Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1274-87. PubMed ID: 15275710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Radioimmunotherapy with 90Y-ibritumomab tiuxetan in lymphomas].
    Setoain X; López-Guillermo A; Ruiz A; Pons F
    Rev Esp Med Nucl; 2006; 25(1):55-68; quiz 69-70.. PubMed ID: 16540015
    [No Abstract]   [Full Text] [Related]  

  • 14. Radioimmunotherapy as a therapeutic option for Non-Hodgkin's lymphoma.
    Macklis RM
    Semin Radiat Oncol; 2007 Jul; 17(3):176-83. PubMed ID: 17591564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicenter phase II clinical study of iodine-131-rituximab radioimmunotherapy in relapsed or refractory indolent non-Hodgkin's lymphoma.
    Leahy MF; Seymour JF; Hicks RJ; Turner JH
    J Clin Oncol; 2006 Sep; 24(27):4418-25. PubMed ID: 16940276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-dose, fractionated radioimmunotherapy for B-cell malignancies using 131I-Lym-1 antibody.
    DeNardo GL; DeNardo SJ; Lamborn KR; Goldstein DS; Levy NB; Lewis JP; O'Grady LF; Raventos A; Kroger LA; Macey DJ; McGahan JP; Mills SL; Shen S
    Cancer Biother Radiopharm; 1998 Aug; 13(4):239-54. PubMed ID: 10850360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma.
    Knox SJ; Goris ML; Trisler K; Negrin R; Davis T; Liles TM; Grillo-López A; Chinn P; Varns C; Ning SC; Fowler S; Deb N; Becker M; Marquez C; Levy R
    Clin Cancer Res; 1996 Mar; 2(3):457-70. PubMed ID: 9816191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How and why does radioimmunotherapy work?
    Macklis RM
    Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1269-71. PubMed ID: 15275708
    [No Abstract]   [Full Text] [Related]  

  • 19. Immunotherapy for low-grade non-hodgkin secondary lymphoma of the orbit.
    Esmaeli B; Murray JL; Ahmadi MA; Naderi A; Singh S; Romaguera J; White CA; McLaughlin P
    Arch Ophthalmol; 2002 Sep; 120(9):1225-7. PubMed ID: 12215104
    [No Abstract]   [Full Text] [Related]  

  • 20. Tumour targeting and radiation dose of radioimmunotherapy with (90)Y-rituximab in CD20+ B-cell lymphoma as predicted by (89)Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab.
    Muylle K; Flamen P; Vugts DJ; Guiot T; Ghanem G; Meuleman N; Bourgeois P; Vanderlinden B; van Dongen GA; Everaert H; Vaes M; Bron D
    Eur J Nucl Med Mol Imaging; 2015 Jul; 42(8):1304-14. PubMed ID: 25792453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.